CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,558 | -24.1% | 34,331 | -6.1% | 0.02% | -11.8% |
| Q2 2023 | $2,053 | -14.1% | 36,563 | -30.8% | 0.02% | -15.0% |
| Q1 2023 | $2,389 | +131.0% | 52,820 | +107.6% | 0.02% | +33.3% |
| Q4 2022 | $1,034 | -99.9% | 25,441 | +47.7% | 0.02% | 0.0% |
| Q3 2022 | $1,125,000 | -4.3% | 17,220 | +10.9% | 0.02% | +25.0% |
| Q4 2021 | $1,176,000 | +13.6% | 15,522 | +67.9% | 0.01% | -14.3% |
| Q3 2021 | $1,035,000 | +238.2% | 9,246 | +267.8% | 0.01% | +250.0% |
| Q1 2021 | $306,000 | -65.8% | 2,514 | -57.0% | 0.00% | -55.6% |
| Q4 2020 | $894,000 | +237.4% | 5,842 | -6.4% | 0.01% | -40.0% |
| Q1 2020 | $265,000 | – | 6,242 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |